Trial Profile
A Drug-drug Interaction Study Between the Novel Anti-HCV Agent Daclatasvir and the Antiretroviral Agents Atazanavir/Ritonavir or Atazanavir/Cobicistat in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Feb 2022
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Atazanavir; Cobicistat; Ritonavir
- Indications Hepatitis C
- Focus Pharmacokinetics
- Acronyms DATE-4
- 20 Oct 2016 Results published in the Journal of Antimicrobial Chemotherapy
- 25 Jan 2016 Status changed from not yet recruiting to completed, as reported by ClinicalTrials.gov.
- 08 Oct 2015 New trial record